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ABSTRACT
It has been suggested that binding of anti-double­
stranded DNA antibodies to cell surfaces, followed by 
internalization and nuclear binding (so called in vivo 
ANA) is of pathophysiological significance for tissue 
dam age In systemic lupus erythematosus. We have 
shown before that pathogenic antinuclear antibodies 
complexed to nucleosomal antigens can bind to 
heparan sulfate in the glomerular basement mem­
brane in vivo. Because nucleosomes are also re­
ported to bind to the cell surface, we hypothesized 
that in vivo ANA is a  property of antinuclear antibod­
ies bound to nucleosomal antigens. Therefore, we 
studied three antinucleosome monoclonal antibod­
ies (mAb) that exhibit in vivo ANA as seen by immu­
nofluorescence in mice inoculated intraperitoneally 
with the hybridoma producing the mAb. The same 
mAb complexed to nucleosomal antigens after intra­
venous injection into mice induced in vivo ANA, in 
contrast to purified noncomplexed mAb. To study this 
in more detail, we incubated complexed mAb with 
various cell lines and found binding to the cell surface 
and subsequent internalization into cytoplasmic vesi­
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cles. However, no binding to the nucleus was ob­
served by immunoelectron microscopy (1EM) and 
confocal laser microscopy. Noncomplexed mAb did 
not bind to the cell surface. Next, from mice bearing 
the hybridomas producing the mAb intraperitoneally, 
a small part of the kidney was snap frozen in liquid N2) 
fixed with acetone, and studied in immunofluores­
cence, whereas the remaining part of the kidney was 
fixed in vivo by renal perfusion with a mixture of 0.01 M 
sodium periodate, 0.075 M lysine HCI, 0.0375 M 
Na2HP04, and 2% paraformaldehyde (PLP) and stud­
ied in both immunofluorescence and IEM. fn the 
acetone-fixed kidney sections obtained without in 
vivo fixation we again observed in vivo ANA. How­
ever, after In vivo PLP perfusion fixation, no nuclear 
binding was found. In IEM, localization in cytoplasmic 
vesicles was seen, in conclusion, antinucleosome 
antibodies complexed to nucleosomal antigens can 
bind to the cell surface and are transported into the 
cytoplasm, but do not bind to the nucleus. The re­
ported nuclear localization of antinuclear antibodies 
is caused by a fixation artifact.
Key Words: Systemic lupus erythematosus, antlnucfeor anti­
bodies, monoclonal antinucleosome antibodies In vivo ANA
Systemic lupus erythematosus (SLE) is an auto­immune disease that affects many organs in the body. Antinuclear autoantibodies are the hallmark of 
the disease, especially anti-double-stranded DNA 
(dsDNA) antibodies (1). These anti-dsDNA antibodies 
are thought to be responsible for most of the tissue 
damage in this disease, although the mechanisms by 
which these lesions axe produced in the various or­
gans is still a matter of debate. It has been proposed 
that anti-dsDNA antibodies are able to bind to cell 
surface-bound DNA (2) or, alternatively, directly via 
cross-reactivity with cell surface proteins (3). This 
binding may lead to cell damage, for instance en­
hancement of apoptosis of rat mesangial cells (4). 
Others mentioned that cell surface-bound anti- 
dsDNA antibodies were internalized and that these 
antibodies were subsequently transferred to the nu­
cleus leading to derangement of cell functions (5,6). 
However, one of the first authors who described the 
binding of anti-dsDNA antibodies to cell surface pro­
teins (7) later discovered that this binding was caused 
by the intermediary action of nucleosomes or DNA/
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histone complexes bound to the antibodies (8). Others 
found that nucleosomes or DNA/histone complexes 
could bind to cell surfaces, probably via a DNA recep­
tor inducing cytokine production (9). At this moment, 
it is still unclear whether the binding of nuclear 
material to cell surfaces, alone or complexed to anti­
bodies, is a charge-related phenomenon or mediated 
via a specific receptor. In favor of a charge-dependent 
interaction is our finding that antinucleosome anti­
bodies complexed to nucleosomal antigens are able to 
bind to the glomerular basement membrane (GBM) in 
viuo, through an interaction with the negatively 
charged heparan sulfate in the GBM (10).
These antinucleosome antibodies are antibodies 
that bind to the nucleosome, but not to its constitu­
ents, hist ones and DNA. These antibodies have been 
described in murine (11-14) and human SLE (15,16), 
but also in other diseases (17,18). Their relevance for 
SLE was reviewed recently (19). When we inoculated 
in naive mice hybridomas producing the antinucleo­
some monoclonal antibody (mAb) that showed the 
above-de scribed GBM binding, we invariably observed 
in vivo nuclear binding of antinuclear antibodies (in 
vivo ANA) in kidney sections by immunofluorescence 
(IF). This nuclear staining can be frequently observed 
in sections of kidneys from patients with SLE or lupus 
mice, and is sometimes explained as a smearing arti­
fact occurring during sectioning of the tissue. Others 
state that this nuclear staining is the result of an 
active process in vivo (5,6). In this study we tested the 
hypothesis that in vivo ANA is produced by antibodies 
complexed to nucleosomal antigens. In this perspec­
tive the complexed autoantibody binds to the cell 
surface via nucleosomal material and, after binding, 
the complex is internalized. We also analyzed whether
this internalization iiltimately leads to nuclear bind- 
tog.
MATERIALS AND METHODS 
Preparation and Characterization of Pure 
Noncomplexed Antibodies and Antibodies 
Complexed to Nucleosomal Material
Three mAb (Clones 2, 32, and 34) derived from lupus mice 
were used. By purification on a protein A-Sepharose column 
under physiological conditions (Procedure I), high salt con­
ditions (Procedure II), or DNase treatment followed by high 
salt conditions (and in the case of mAb 34, additional sepa­
ration of hi stone-bound mAb on a DNA-cellulose column) 
(Procedure III), antibodies complexed to nucleosomal m ate­
rial (Procedures I and II) or pure noncomplexed antibodies 
(Procedure III) were obtained as described before (10).
Purified and complexed antibodies were tested in the Farr 
assay and in ELISA (anti-dsDNA, antihistone, and antinu­
cleosome) as described (10). Composition and antigen reac­
tivities of the antibody preparations used have been pub­
lished (10) and are summarized in Table 1.
mAb 2 and 32 are antinucleosome mAb, which in purified 
form (purification Procedure III) only recognize the intact 
nucleosome and not its components, his tones or DNA. In 
pure form (Procedure III) mAb 34 also recognizes histones, 
but its reactivity with the intact nucleosome is much stron­
ger. All three mAb only show DNA reactivity when they are 
complexed to nucleosomal antigens (purification Procedures 
I and II).
In Vivo Studies
Hybridoma Inoculation. Hybridoma cells producing the 
mAb (5 X 10s cells per mouse) were inoculated intraperito­
neally in 8-week-old BALB/c mice (N -  3 per mAb), which 
were primed 8 days before with pristane. As controls three 
mice were inoculated with pristane alone and with the hybri-
TABLE 1. Composition of bound complexes (Panel A), reactivity In Farr assay and various ELISA (Panel B) of 
the different mAb preparations obtained after purification under physiological conditions (I), high salt 
conditions (II), or DNase treatment followed by high salt conditions (and, in the case of mAb 34, additional 
separation of histone-bound mAb on a DNA-cellulose column) (III) (Reproduced with permission from J Clin 
Invest 1994;94:568-577)
mAb 2 mAb 32 m Ab 34
Procedures 1 II III 1 II III 1 II III
A. Composition
Histonesa + + — + + + + — +  + +  +  + —
DNAb + — + + — + ± —
B. In vitro reactivity
Farrc 6 25 3 70 75 3 17 57 3
ELISAd
DNA 178 227 36 98 100 1 178 200 16
Histone 55 90 <1 4500 187 1 1777 800 494
Nucleosom e 3500 4800 3000 5000 7600 5400 7500 12000 12000
a Histone content as assessed on SDS-PAGE; the Intensity of the histone staining was scored sem[quantitatively by comparing the Intensity of the 
staining with that of the heavy and light chain,
b Presence of DNA fragments (of predominately 120 base pairs) as assessed after labeling with 32P. 
c Percentage precipitation of labeled DNA per 12 /xg of IgG; values <3% are regarded as negative, 
d Titer/mg IgG,
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doma-producing WT1, a mouse immunoglobulin (Ig) G2a 
antihuman CD7 mAb. Two days after development of ascites 
the animals were euthanized, ascites and blood was collected 
in EDTA vials and stored at ~20°C, the kidneys were flushed 
with phosphate-buffered saline (PBS) and snap frozen in 
liquid N2.
In an additional experiment only a small part of the kidney 
was snap-frozen in liquid N2 after flushing with PBS and 
used for IF. The remainder of the kidney was perfused during
10 min with a mixture of 0.01 M sodium periodate, 0.075 M 
lysine HC1, 0.0375 M Na2HP04t and 2% paraformaldehyde 
(PLP). This was done to obtain in vivo fixation. Thereafter, the 
kidney was cut into small pieces (5 X 5X 1 mm) and 
immersed in PLP for another 3 h, A small part of tissue was 
used for IF, whereas the remaining pieces were used for 
immunoelectron microscopy (IEM). To this end they were 
washed in PBS for 30 min, cryoprotected by immersion in 
80% wt/vol sucrose in PBS for 1 h, and snap frozen in liquid 
N2.
Intravenous Injection. Complexed (Procedure I or II) and 
noncomplexed mAb (Procedure III), 1 mg Ig in 500 fiL PBS, 
were injected intravenously in 6- to 8-week-old BALB/c mice. 
After 5 or 45 min kidneys were flushed with PBS, taken out, 
and snap frozen in liquid Na. At 5 min three mice injected 
with noncomplexed and three mice injected with complexed 
mAb were studied (mAb 32 and 34). At 45 min three mice 
injected with noncomplexed mAb and seven mice injected 
with complexed mAb were studied (mAb 2, 32, and 34). In 
addition two mice were injected with a control IgG2a mAb 
(WT1).
Immunohistology of Kidney Tissue
Direct IF was performed on 2-/xm cryostat sections. Sec­
tions were fixed for 5 min in cold acetone and air dried. Next, 
sections were incubated for 1 h at room temperature with 
F(ab)2 fluorescein isothiocyanate (FITC)-labeled sheep anti­
mouse IgG (Cappel, Organon Teknika NV, Turnhout, Bel­
gium) diluted 1:750 in P B S /1% wt/vol BSA, and 4% normal 
rat serum. After washing, the sections were embedded in 
Aquamount (BDH Ltd, Poole, England) and examined with a 
Zeiss fluorescence microscope.
Double labeling with 4,6-diamidino-2-phenylindole (DAPI, 
Sigma, St Louis, MO) was performed by diluting DAPI (1 
fjig/mL) in Aquamount.
For IEM, 20-jitm sections were incubated with a peroxi­
dase-labeled rabbit antimouse Ig diluted 1:20 (Dakopatt, 
Copenhagen, Denmark) and washed three times with PBS. 
Subsequently, the sections were preincubated in diamino- 
benzidine medium (0.05% diaminobenzidine wt/vol in Tris) 
for 10 to 15 min» followed by diaminobenzidine medium with 
addition of H202 to a final concentration of 0,03% vol/vol. 
The sections were washed in distilled water, postfixed in 0,1 
M phosphate-buffered 1% wt/vol 0 s 0 4 for 30 min at room 
temperature, dehydrated, and embedded in Epon 812. Thin 
sections were prepared on a LKB ultratome and examined 
unstained in an electron microscope (Jeol 1200 EX2, Jeol 
Europe BV).
Binding of Complexed and Noncomplexed 
mAb to Surfaces of Cells in Culture
For these experiments three cell lines were used, CEM and 
PEER are human T cell lines, that are Fc receptor negative. 
HL60 is a human myeloid cell line, which bears Fc receptors
I and II. Cells were cultured in RPMI 1640, dutch modifica­
tion (ICN, Costa Mesa, CA), supplemented with 2 mM glu­
tamine and 1 mM pyruvate containing gentamycin (40 /xg/ 
mL) and 5% (vol/vol) fetal calf serum (FCS) (Life 
Technologies, Gaithersburg, MD). Only cultures less than 3 
weeks old with a viability of >95%, as assessed with trypan 
blue, were used. Cells in suspension (100 juL, 5 x 106 
cells/mL in PBS/1%BSA) were incubated with complexed 
mAb, noncomplexed mAb, or an irrelevant mouse lgG2a mAb 
(100 juL, 200 fjig/mL in PBS) for 30 min at 4°C, After washing 
twice with PBS/1%BSA they were incubated with FITC- 
conjugated F(ab)2 sheep antimouse IgG (100 /xL, diluted 
1:300 in PBS / 1%BSA) (Cappel, Organon Teknika) for 30 min 
at 4°C. After washing the cells twice again with PBS / 1%BSA 
the fluorescence intensity was determined with a Fluores­
cence Activated Cell Sorter (Coulter Electronics Ltd, Luton, 
UK).
To analyze whether charged molecules could influence the 
cellular binding, complexed antibodies, mAb WT1 (mouse 
lgG2a antihuman CD7) and mAb 1210 (mouse IgG2a anti­
human class II) were incubated with PEER cells in the 
presence of heparin 3 jug/mL, and subsequently analyzed by 
Fluorescence Activated Cell Sorter as described above.
Internalization and Ultrastructural Intracellular 
Localization of Bound mAb
PEER cells In suspension ( 1300 ;xL; 5 X 106 cells/mL) were 
incubated with pure noncomplexed or complexed mAb for 30 
min, 2, 5, or 18 h in RPMI containing 5% FCS at 37°C. After 
incubation the cells were fixed in 2% paraformaldehyde 
(PF)/0,1 M phosphate biiffer (PB), pH 7.4, for 1 h at room 
temperature. The cell suspension was divided in two parts. 
One part was used for IF and the other part of the suspension 
for IEM, In addition a pulse-chase experiment was per­
formed. Complexed mAb was incubated for 30 min at 4°C 
with cells (1300 ßU 5 X 106 cells/mL) in RPMI containing 
10% FCS. Cells were washed three times in PBS containing 
1% BSA to remove unbound mAb. Next cells were incubated 
in RPMI containing 10% FCS at 37°C and studied by confocal 
laser microscopy at different time points (5 min, 30 min, 2 ,5 , 
and 18 h).
Immunofluorescence. The cells were spun down in O.C.T, 
Tissue-Tek compound (Miles, Elkhart, IN) and snap frozen in 
liquid N2. Six-micrometer sections were cut in a cryostat 
(Micron) at -20°C , picked up on silan-coated slides at 
-20°C, and air dried. After a brief rinse in PBS/0.05% Tween 
(PBST), the sections were incubated with 1% normal goat 
serum/PBST for 30 min to block nonspecific protein binding. 
After removal of the latter solution, the sections were incu­
bated for 1 h in a moist chamber at room temperature with 
oat antimouse FITC (Cappel, Organon Teknika) diluted 1:80 
in PBST, Then the slides were rinsed with three changes of 
PBST for 10 min each and mounted with Mowiol (Hoechst, 
Frankfurt am Main, Germ any)/2.5% Na N3. The sections 
were viewed with a Zeiss fluorescence microscope.
Immunoelectron Microscopy. The cells were spun down in 
10% gelatin/0.1 M PB, pH 7.4, andpostfixed in 2% PF/0.1 M 
PB overnight at 4°C. The next day they were cut in small 
blocks, infiltrated with 2.3 M sucrose, placed on copper 
stubs, and snap frozen in liquid N2. Ultrathin cryosections 
(80 nm) were cut with a cryoultramicrotome (Leitz Ultracut- 
FCS), picked up with 2.3 M sucrose, and placed on formvar- 
coated copper grids. After blocking the nonspecific protein 
binding with PB S/0.15% glycine/0.1% BSA/0.1% gelatin, 
pH 7.4 (PBSG), for 30 min the sections were incubated 
overnight at 4°C in a moist chamber with rabbit-antimouse 
IgG (Cappel) 1:500/PBSG, The next day the grids were rinsed
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three times with PBSG and incubated with protein-A gold 10 
nm/1% BSA/PBS for 1 h at room temperature. After rinsing 
again three times in 0.1 M PBS and 3 times in milli-H20  the 
grids were placed on drops of a methylcellulose /ur any lac- 
etate (9:1) solution for 10 min on ice and picked up with 
stainless steel loops. Excess methylcellulose was removed by 
filter paper and the grids were air dried. The sections were 
viewed with a JEOL 1010 electron microscope.
Confocal Laser Microscopy. After fbdng with 1% PF/0.1 M 
PB the cells were spread on silan-coated slides and air dried. 
The cells were permeabilized with 0.5% saponine/0.1 M PB 
for 30 min and incubated as described for the immunofluo­
rescence technique. After mounting with Mowiol/2.5% NaN3 
the cells were viewed with the confocal laser microscope 
(MRC 600, Biorad, Hemel Hempstead Herts, UK).
RESULTS 
In Vivo ANA after Intraperitoneal Hybridoma 
Inoculation in Mice
BALB / c mice (N = 3 per clone) were injected intra­
peritoneally with 5 X 106 hybridoma cells. In ascites 
and blood samples from mice inoculated with antinu­
cleosome-producing hybridoma cells anti-HS and an­
ti-DNA reactivity was detected in contrast to control 
mice carrying the hybridoma producing the antihu­
m an CD7 mAb WT1 (data not shown). Previously, we 
had shown that these antinucleosome mAb only dis­
play anti-HS or anti-DNA reactivity if they are com­
plexed to nucleosomes (10). In kidney sections of mice 
bearing either of the three hybridomas intraperitone­
ally a consistent in vivo ANA was observed in IF (Figure
1), DAPI double labeling revealed that all nuclei were 
ANA positive (data not shown). As we have shown 
previously with in vivo renal perfusion of nucleosome- 
complexed antinucleosomal mAb (10), we observed 
also glomerular binding in this experimental setup 
{Figure 1). Mice inoculated with pristane alone or the 
control mAb WT1 showed no nuclear binding and only
Figure 1. Direct immunofluorescence of kidneys of mice 
inoculated intraperitoneally with the hybridoma-producing 
m A b 32 showing in vivo ANA. Glomerular deposits are also 
observed (original magnification, x300).
limited glomerular mesangial deposition of IgG2a 
(data not shown).
In Vivo ANA of Complexed and 
Noncomplexed Antibodies after Intravenous 
Injection
To evaluate whether this nuclear binding was* as we 
hypothesized, due to antibodies complexed to nucleo­
somes, we injected complexed antibodies intrave- 
noiisly in mice. At 5 min again binding to glomerular 
capillary loops and some in vivo ANA was found by IF 
(Figure 2A), whereas after intravenous injection of 
pure noncomplexed mAb, no glomerular binding and 
a very faint in vivo ANA was observed (Figure 2B). 
When kidneys were studied 45 min after intravenous 
injection of complexed antinucleosomal mAb the an­
tibodies were found in the cell nuclei by IFt whereas 
some glomerular binding remained (Figure 2C), Find- 
ings in all three tested antinucleosome mAb were 
essentially the same, except for complexed mAb 2, 
which did not show glomerular binding but only in 
vivo ANA after 45 min. Double labeling with DAPI 
revealed that the nuclei of all cells were positive. When 
purified noncomplexed mAb were injected, only a very 
faint staining of nuclei, as shown in Figure 2B, was 
observed after 45 min. So, nuclear binding was a 
property of nucleosome-complexed antibodies. Injec- 
tion of control mAb WT1 only led to some mesangial 
binding, neither nuclear nor glomerular binding was 
observed.
Binding of Complexed and Noncomplexed 
mAb to Surfaces of Cultured Cells.
To analyze the course of events leading to in vivo 
ANA, we turned to binding studies with well defined 
cell lines. Noncomplexed antinucleosome mAb 
showed hardly any binding to the cell surface of CEM, 
PEER, or HL60 cells (Table 2). However, when the 
antibodies were complexed to nucleosomes a marked 
binding was observed. In most cases binding of com­
plexed antibodies containing less DNA (obtained by 
Procedure II) was higher than that of complexes of the 
same mAb, obtained by Procedxire I, containing con­
siderably more DNA. Cell surface binding was seen 
with all three cell lines studied, irrespective of the 
presence of Fc receptors, because CEM and PEER are 
Fc receptor negative. Fluorescence intensity observed 
after incubation of control IgG2a mAb in the same 
concentration did not exceed background levels (Table
2) except for mAb WT1, which was positive on CEM 
and PEER cells, because these cells express the CD7 
antigen recognized by WT1*
To analyze whether charged molecules are impor­
tant for the cellular binding, complexed antibodies 
were incubated with PEER cells in the presence of 
heparin. Heparin blocked this binding, whereas the 
binding of the positive control (mAb WT1, antihuman 
CD7), or the negative control (mAb 1210, antihuman 
class II) was not affected (Table 3).
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Figure 2. Direct immunofluorescence of mouse kidneys after 
Intravenous injection of pure antibodies (mAb 32) or anti­
bodies complexed to nucleosomal antigens. When com­
plexed antibodies are injected GBM binding and some in 
vivo ANA is observed after 5 min (A: original magnification, 
X300), and after 45 min oniy marked nuclear binding (in 
vivo ANA) is found (C: original magnification, X4ÛQ). When
Internalization after Binding of Complexed 
Antinucleosome mAb to Cultured Cells
To study whether cell surface binding of antibodies 
complexed to nucleosomes leads to nuclear binding, 
complexed mAb were incubated with cells. Internal­
ization of antibodies was found after 2 h, increasing 
with longer incubation times (5 and 18 h}. Antibodies 
were localized in cytoplasmic vesicles (Figure 3). In the 
pulse-chase experiment after initial binding to the cell 
surface (Figure 4A), the antibody rapidly appeared in 
the cytoplasm (Figure 4B). After 18 h of incubation 
capping of residual mAb was observed. In none of 
these experiments, repeated several times, nuclear 
binding of internalized mAb in living cells was seen.
In both sets of experiments viability of the cells was 
not affected by internalization of mAb as assessed by 
Fluorescence Activated Cell Sorter analysis.
Effects of Fixation on Localization of mAb 
in Vivo
Because, in the previous experiments, where no 
nuclear binding was observed, fixation was carried 
out with paraformaldehyde, we questioned whether 
the in vivo ANA was related to the fixation technique. 
To this end we analyzed in a separate experiment the 
effect of the different fixation procedures carried out 
on the same kidney. After intraperitoneal administra­
tion of the hybridoma in mice, kidney tissue was fixed 
in parallel either by freezing in liquid N2, subsequent 
cutting of sections and acetone fixation, or by initial in 
vivo fixation with PLP and subsequent processing of 
tissue. After cryopreservation and fixation with ace­
tone in IF in vivo ANA was observed identical with that 
shown in Figure 1. After fixation of the remaining part 
of the same kidney by perfusion with and immersion 
in PLP, no nuclear binding was found in this material 
by IF (data not shown), whereas by IEM the mAb were 
localized in cytoplasmic vesicles (Figure 5), compara­
ble with the localization found in the in vitro experi­
ments with living cells with confocal laser microscopy.
DISCUSSION
In vivo ANA (in vivo binding of autoantibodies to the 
cell nucleus) as examined by IF has been described by 
numerous authors, in tissue sections of both patients 
with SLE (20-22) or other autoimmune diseases (23— 
25), Recently, it was reported that certain anti-dsDNA 
mAb injected into experimental animals reproducibly 
showed intranuclear localization, whereas others 
were deposited extracellularly within glomeruli 
and/or blood vessels (5). This intranuclear localiza­
tion of anti-dsDNA mAb was a time- and ATP-depen­
dent phenomenon. Before internalization binding to a 
cell surface receptor was demonstrated (6). It was
purified mAb are injected at 5 (B: original magnification, 
X400) and 45 min no glomerular binding and very faint In 
vivo ANA are observed.
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TABLE 2. Binding of complexed and noncomplexed mAb to cell surfaces of CEM, PEER, and HL60 cells0
mAb PurificationProcedure0
Presence of
CEM PEER HL60
Histonesc DNAd
1 1 1
2 HI — - 4 5 3
2 II + 23 59 24
2 1 + + 18 21 9
32 III — - 3 6 12
32 II + + ± 33 63 100
32 1 + + + + 11 Ó ND
34 III — ------ 3 4 13
34 II ■4- 54 54 88
34 I + + + 19 17 26
WTle — — 34 67 Ó
1210f — — 1 1 ND
° The binding is expressed as mean fluorescence intensity, The baseline negative control without mAb is set at 1, and all other measurements are 
adjusted accordingly, Data are derived from a representative experiment, 
b For description of purification procedures see Table I. 
c Histone content as assessed on SDS-PAGE,
d Presence of DNA fragments as assessed after labeling with 32P (see text),
â WT) Is an lgG2a mouse mAb toward human CD7, which is expressed on CEM and PEER ceils, but not on HL60, 
f 1210 Is an lgG2a mouse mAb against human HLA class II, which Is not expressed on CEM and PEER, ND, not determined,
TABLE 3. Binding of complexed mAb to cell surfaces 
of PEER cells with and without heparin
PBS Heparin (3 /tg/mL)
mAb 32 (procedure 11) 54 8
WTla 23 30
1210b 3 3
- 1 1
a WTl, antihuman CD7 (present on PEER cells), 
b 1210, antihuman HLA class II (not present on PEER cells),
claimed that this in vivo nuclear binding had major 
pathological consequences like decreased cell prolif­
eration, increased protein synthesis (26), glomerular 
hypercellularity and proteinuria (5). We also observed 
nuclear binding when hybridomas producing antinu­
cleosome mAb were inoculated intraperitoneally in 
mice. Because in the ascites of these mice nuclear 
material is released from dying hybridoma cells, im­
mune complexes are formed in vivo (27), which was 
confirmed by the finding of anti-HS and anti-dsDNA 
reactivity in the ascites and the circulation of these 
mice. So, this in vivo ANA might be a feature of 
antinucleosome antibodies complexed to nuclear an­
tigens. Indeed, when we injected complexed antinu­
cleosome antibodies intravenously into mice, strong in 
vivo ANA was observed after 45 min. After 5 min GBM 
binding was found which was similar to what we 
observed after renal perfusion of these complexed 
antibodies (10). We found that nuclear binding of mAb 
was not restricted to the kidney, but was also found in 
two other organs that we analyzed (liver and skin). In 
theory, the differences we found between complexed 
and noncomplexed mAb could be attributed to differ­
ences in clearance kinetics. This is unlikely, however,
Figure 3. Immunoelectron microscopy of iymphold cells 
incubated with antibodies (mAb 32) complexed to nucleo­
somal materiai. After 5 h gold particles, indicating antibody 
localization, can be found In cytoplasmic vesicles. The 
nuclear rim is Indicated by arrows. No nuclear binding is 
observed (original magnification, x63,000).
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Figure 4. Incubation of antibodies (mAb 32) complexed to 
nucleosomal material with lymphoid cells. By confocal laser 
microscopy in a pulse-chase experiment after initial binding 
to the cell surface (A: original magnification, X150Û), the 
antibody rapidly appears in the cytoplasm (Insert, B: original 
magnification, X3ÛQQ), Most importantly these studies did 
not reveal any nuclear binding In living cells.
because the complexed antibodies are cleared more 
rapidly from the circulation via Fc and complement 
receptors than noncomplexed antibodies. So, if a dif­
ference in clearance will affect the results, it would 
rather decrease the nuclear appearance of complexed 
antibodies.
Our observations provide evidence that in vivo ANA 
is a feature of antibodies bound to nucleosomal ma­
terial. Some of the discrepancies in the literature on 
this subject might therefore be explained by impuri­
ties of the antibody preparations containing variable 
amounts of nucleosomal antigens. This nucleosomal 
material can easily be copurified with antinuclear 
antibodies (10) and be missed on sodium dodecyl 
sulfate-polyaciylamide gel electrophoresis (SDS-PAGE) 
when only Coomassie staining is used.
Before in vivo ANA can develop, autoantibodies have 
to bind to the cell surface and have to be transported 
through the cytoplasm to the nucleus. Binding of 
anti-dsDNA mAb to the cell surface has been de-
Figure 5. Influence of fixation procedure on in vivo ANA. A 
part of the same kidney used for IF in Figure 1 was fixed by in 
vivo perfusion and subsequent immersion in PLP. By IEM no 
nuclear binding is observed, Antibodies are localized in 
cytoplasmic vesicles, one of which is indicated by an arrow 
(original magnification, x6000).
scribed before (28) and was attributed to the binding 
to the so-called “lupus associated membrane protein” 
(7). Soon, it was shown that this binding was not a 
direct cross-reactivity of the mAb with lupus associ­
ated membrane protein, but that it occurred via his- 
tones and DNA (8,29)* These findings were challenged 
by a more recent paper describing again that anti- 
dsDNA mAb could directly bind to cell surfaces (3). 
However, one of the mAb utilized in this latter study 
{PME 77) was used by Jacob et a l  {8) to identify that 
binding occurred via his tones and DNA. In line with 
our observations (10), PME 77 shows only weak reac­
tivity with DNA and strong reactivity with nucleo­
somes (8). So this mAb resembles the antinucleosome 
mAb used in this study.
We found only very weak binding of pure noncom­
plexed mAb to cell surfaces whereas the complexed 
antibodies bound considerably stronger. For our ex­
periments we only used fresh cell cultures with a 
viability of >95%. This is important because cells in 
culture can be a rich source for nucleosomal material
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released in the supernatant which may mediate sub­
sequent binding of purified antibodies. Using cell 
cultures with a poor viability, we found considerable 
binding of purified noncomplexed mAb (data not 
shown).
The binding of antibodies to cell surfaces vta nucleo­
somes is in line with findings of others, showing 
binding of nucleosomes to cell surfaces, maybe via a 
DNA receptor (9). It is also possible that binding of 
complexed antibodies is a charge-related phenome­
non, This view is supported by our finding that com­
plexed antibodies harboring less DNA bind better to 
the negatively charged cell surface and by the fact that 
heparin, which is strongly negatively charged, could 
block the binding completely. Recently, we described 
that heparin is also able to block the binding of these 
complexed antibodies to the GBM (30,31). Also for this 
binding, we postulated that it is due to charge. The 
positively charged histones in the nucleosome are 
thought to niter act with the negatively charged hepa­
ran sulfate in the GBM.
When we incubated complexed antibodies with cells 
we found cytoplasmic localization of mAb, but did not 
observe any nuclear binding despite 18 h of incuba­
tion. Therefore, we returned to the in vivo experiments 
and found that in the same kidney nuclear binding 
can be detected when the tissue is processed conven­
tionally for IF, whereas no nuclear localization is 
found when in vivo PLP fixation is used. By IEM, 
localization in cytoplasmic vesicles was observed, re­
sembling the picture found with the confocal laser 
microscopy in the in vitro experiments. This suggests 
that when tissue is processed for conventional IF the 
procedure leads to disruption of intracellular struc­
tures, which allows antibodies present within the 
cytoplasm to diffuse and to bind to the cell nucleus. 
Apparently this occurs after cutting of the sections 
before the acetone fixation. Another possibility is that 
acetone fixation does not prevent migration of anti­
bodies after the fixation procedure, This nuclear local­
ization of mAb is prevented by PLP fixation. In line 
with this observation is that in previous studies de­
scribing the in vivo ANA conventional IF techniques 
were used, with acetone fixation (20,23,32,33). Of 
course, in vivo perfusion fixation with PLP is not 
feasible for human biopsies. We did not find reports 
about in vivo ANA after PLP immersion fixation. There­
fore, whether in vivo ANA as found in SLE patients is 
due to in vivo binding of auto antibodies to the nucleus 
or to a fixation-related artifact, is not clear yet, al­
though our studies suggest that the latter explanation 
is true.
A similar phenomenon has been described for the 
perinuclear binding of antineutrophil cytoplasmic au­
toantibodies (p-ANCA) due to antibodies directed 
against myeloperoxidase (34). Nevertheless, one has 
to be cautious to extrapolate findings from in vitro 
analysis of human cell lines to binding observed in 
vivo  in mouse kidney cells. Very interestingly, how­
ever, it was recently reported that nucleosomes are
able to bind to the cell surface of mouse mesangial 
cells in vivo (35), providing a link between the two 
experimental setups we describe.
Furthermore, one should realize that most previous 
studies analyzing nuclear penetration of auto antibod­
ies used anti-dsDNA (6,36) and not antinucleosome 
antibodies. Therefore, it can not be excluded that the 
discrepancy between our and these studies is due to 
the difference in antibody specificity. Nonetheless, our 
study raises serious doubts whether in vivo ANA 
exists. It is claimed that in ufuo nuclear binding of 
autoantibodies can lead to tissue damage (5). The fact 
that in vivo ANA is often encountered in noninflamed 
tissue (33) may be an argument that in these in­
stances nuclear binding is a consequence of the fixa­
tion process.
Although our results indicate that in vivo ANA is an 
artifact, we want to stress that the phenomenon of in 
vivo ANA is a characteristic of pathogenic nephrito- 
genic antinuclear autoantibodies complexed to nu­
cleosomal antigens. The same complexed autoanti­
bodies are able to bind to the GBM in vivo and activate 
complement (10) and are related to onset (37) and 
exacerbations (38) of nephritis in SLE patients. A 
similar suggestion has been put forward by Ohnishi 
and colleagues, who suggested that pathogenic an Li­
ds DNA antibodies are capable both of binding to 
nuclei in vivo and to renal basement membranes via 
DNA/histone (39). Furthermore, cellular binding or 
intracytoplasmic uptake of these complexed autoan­
tibodies may be responsible for the derangement of 
cellular functions as observed by others like interfer­
ence with apoptosis (4,19), cellular proliferation 
(5,26), protein synthesis (5), or proteinuria (26). Fi­
nally, our s tudies indicate that the analysis of in vivo 
ANA is only valid if the tissue is fixed properly.
NOTE ADDED IN PROOF
During the revision of this arLicle, an article was 
published that described the same observation, 
namely, endocytosis of nucleosome-antinucleosome 
complexes by Green monkey fibroblasts. This endocy­
tosis was mediated by putative DNA (180 kd) and 
nucleosome (50 kd) receptors (Eur J Immunol 1996; 
26:472-486).
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